Phase 1 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with an advanced or metastatic solid tumour, including primary brain tumours (tumours that started in the brain).
- People whose tumour has a specific gene change called a BRAF alteration (either a V600 type or a non-V600 Class II/Class III type), detected in tumour tissue and/or a blood test.
- People whose cancer has continued to grow or spread during or after their most recent treatment, and for whom no satisfactory other treatment options are available (applies to certain parts of the trial).
- People with melanoma or colorectal cancer (bowel cancer) who have already received specific previously approved treatments for their cancer type (confirm with trial site for exact requirements).
- For one specific group (melanoma with BRAF V600 mutation): people who have already received treatment with a BRAF inhibitor, a MEK inhibitor, and an immune checkpoint inhibitor therapy.
- For one specific bowel cancer group: people who have received at least 2 cycles of a chemotherapy called 5-FU, have not previously had a BRAF inhibitor or EGFR inhibitor, and — if their cancer has a specific genetic feature (MSI-H/dMMR) — have also received immune checkpoint inhibitor therapy.
- For another specific bowel cancer group: people who have received no more than 2 cycles of 5-FU chemotherapy, have not previously had a BRAF inhibitor or EGFR inhibitor, and — if their cancer has a specific genetic feature (MSI-H/dMMR) — have also received immune checkpoint inhibitor therapy.
Who may not be able to join:
- People who have a brain metastasis (a tumour that has spread to the brain) that is larger than 4 cm in size.
- People who are currently receiving other anti-cancer treatments or certain targeted drug therapies at the time the trial treatment would begin.
- People who have a history of, or currently have, a condition called retinal vein occlusion (a blockage of a blood vessel in the eye), current risk factors for this condition, or a history of degenerative disease of the retina (the back of the eye).
- People who have a neuromuscular disorder (a condition affecting the muscles and nerves) that is associated with raised levels of a muscle enzyme called creatine kinase (CK).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2); Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2); Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2); Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2); Dose interruptions due to AEs (Part 1 and Part 2); Dose dose modifications due to AEs (Part 1 and Part 2); Discontinuations due to AEs (Part 1 and Part 2); Overall response rate (ORR) (Par...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.